US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

9.85

+0.07000.72%

Post-market: 9.850.00000.00%19:34 EST

Volume:61.37K

Turnover:605.56K

Market Cap:3.30B

PE:231.00

High:9.93

Open:9.80

Low:9.80

Close:9.78

52wk High:30.36

52wk Low:8.76

Shares:335.00M

Float Shares:272.00M

Volume Ratio:0.54

T/O Rate:0.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.0426

EPS(LYR):0.0933

ROE:3.14%

ROA:2.08%

PB:7.82

PE(LYR):105.61

Loading ...

Overview Company News Filings

ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed

Telix Pharmaceuticals (ASX:TLX) Valuation After ZIRCON-X Data Highlights TLX250-CDx’s Potential Clinical and Commercial Impact

Simply Wall St.

Citi Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)

3 ASX Growth Stocks With High Insider Ownership Growing Earnings Up To 47%

Simply Wall St.

Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley

ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses

ASX Investment Ideas 3 Stocks With Estimated Undervaluation

Simply Wall St.

Telix Pharmaceuticals Faces Class Action Lawsuit Alleging Misleading Statements Related to Progress of Prostate Cancer Therapy Candidates; Shares Fall 3%

MT Newswires Live

OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer

Citi Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

Does the SEC Probe Challenge Telix Pharmaceuticals' (ASX:TLX) Management Credibility and Investor Confidence?

Simply Wall St.

Telix to Participate in UBS and Jefferies Global Healthcare Conferences

Telix Pharmaceuticals (ASX:TLX): Examining Valuation After SEC Subpoena and Ongoing Legal Probes

Simply Wall St.

Is the SEC Subpoena Shifting the Risk Landscape for Telix Pharmaceuticals (ASX:TLX)?

Simply Wall St.

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

How Does Regulatory Scrutiny Impact Telix Pharmaceuticals (ASX:TLX) Valuation?

Simply Wall St.

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals to Release Shares from Voluntary Escrow

TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging

Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":9.85,"timestamp":1764968400000,"preClose":9.78,"halted":0,"volume":61374,"hourTrading":{"tag":"盘后","latestPrice":9.85,"preClose":9.85,"latestTime":"19:34 EST","volume":9,"amount":88.48,"timestamp":1764981258382},"delay":0,"floatShares":272000000,"shares":335000000,"eps":0.04264,"marketStatus":"Not Yet Opened","change":0.07,"latestTime":"12-05 16:00:00 EST","open":9.8,"high":9.9288,"low":9.8,"amount":605562.344118,"amplitude":0.01317,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.04264,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":0,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":9.78,"postHourTrading":{"tag":"盘后","latestPrice":9.85,"preClose":9.85,"latestTime":"19:34 EST","volume":9,"amount":88.48,"timestamp":1764981258382},"volumeRatio":0.535543195059686},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.08%","roe":"3.14%","lyrEps":0.093266,"volumeRatio":0.535543195059686,"shares":335000000,"dividePrice":0,"high":9.9288,"amplitude":0.01317,"preClose":9.78,"low":9.8,"week52Low":8.76,"pbRate":"7.82","psRate":"4.97","week52High":30.36,"institutionHeld":0,"latestPrice":9.85,"eps":0.04264,"divideRate":0,"volume":61374,"delay":0,"ttmEps":0.04264,"open":9.8,"prevYearClose":15.4,"prevWeekClose":9.95,"prevMonthClose":9.95,"prevQuarterClose":9.57,"fiveDayClose":9.95,"twentyDayClose":9.88,"sixtyDayClose":9.32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758171600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2025-12-05","current":231.003752,"percent":0.85283,"low":113.06761,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"high":383.853933,"avg":210.552558,"sd":66.820434,"marketCap":3320635708.33},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33}],"updateTime":1765176404554},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2589060328","title":"ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed","url":"https://stock-news.laohu8.com/highlight/detail?id=2589060328","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589060328?lang=en_us&edition=fundamental","pubTime":"2025-12-08 06:08","pubTimestamp":1765145280,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited  today announces that the first patienthas been dosed in Part 2  of its ProstACT Global Phase 3 study evaluating its lead prostate cancer therapy candidate TLX591  in patients with metastatic castration resistant prostate cancer . The patient was dosed at the Australian Prostate Centre  in Melbourne, Australia.ProstACT Global is the first Phase 3 trial to combine aPSMA[1]-targeted radio antibody-drug conjugate  therapy administered together with Standard of Care  versus SOC alone. Part 2 of ProstACT Global will enroll approximately 490 patients and is currently recruiting patients in Australia, New Zealand and Canada.As previously agreed with FDA and disclosed to the market, Telix will submit Part 1 data to the United States  Food and Drug Administration  to enable clearance to expand Part 2 of the trial to U.S. sites. A public disclosure of preliminary results from Part 1 of the study will","market":"sh","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/prostact-global-phase-3-update-first-patient-dosed-in-randomized-treatment-expansion-part-1-readout-plans-confirmed-302634831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0149725797.USD","LU1366192091.USD","LU1066051811.HKD","LU2420271590.USD","LU2237443382.USD","XAO.AU","APC","LU0786609619.USD","EMA.AU","LU1496350171.SGD","LU2237443622.USD","LU2237443978.SGD","APC.AU","ASX.AU","BK4141","EMA","LU0170899867.USD","LU1935043536.SGD","XKO.AU","RLT.AU","LU1778281490.HKD","LU0882574139.USD","LU2456880835.USD","TLX","XJO.AU","LU1935043023.USD","BK7142","LU2083900584.USD","BK4139","BK7129","LU1674673691.USD","LU1066051498.USD","TLX.AU","SEC.AU","BK4543","LU1066053197.SGD","LU2236285917.USD","ASX","BK7095","LU2237443549.SGD","BK4526","LU0314104364.USD","BK7067","CTA","LU0053666078.USD","LU1066051225.USD","LU1718418525.SGD","LU1935042488.USD","LU1935042991.SGD","LU0077335932.USD"],"gpt_icon":0},{"id":"2588607073","title":"Telix Pharmaceuticals (ASX:TLX) Valuation After ZIRCON-X Data Highlights TLX250-CDx’s Potential Clinical and Commercial Impact","url":"https://stock-news.laohu8.com/highlight/detail?id=2588607073","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588607073?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:16","pubTimestamp":1764796575,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) just released ZIRCON-X study data showing its TLX250-CDx kidney imaging agent could have changed clinical decisions for almost half of patients, with more than 20% potentially avoiding invasive biopsy.\nSee our latest analysis for Telix Pharmaceuticals.\nDespite the latest ZIRCON-X update highlighting the potential commercial impact of TLX250-CDx, Telix’s recent share price performance has been choppy, with a 1 month share price return of minus 9.68 percent and a...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-after-zircon-x-data-h","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-valuation-after-zircon-x-data-h","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","TLX","BK7067","BK4139","TLX.AU"],"gpt_icon":0},{"id":"2586278496","title":"Citi Sticks to Its Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2586278496","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586278496?lang=en_us&edition=fundamental","pubTime":"2025-11-28 06:35","pubTimestamp":1764282937,"startTime":"0","endTime":"0","summary":"Citi analyst Laura Sutcliffe maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$34.00. According to TipRanks, Sutcl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-its-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"2586047444","title":"3 ASX Growth Stocks With High Insider Ownership Growing Earnings Up To 47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586047444","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586047444?lang=en_us&edition=fundamental","pubTime":"2025-11-26 03:08","pubTimestamp":1764097687,"startTime":"0","endTime":"0","summary":"As the Australian market navigates a mixed landscape, with materials gaining ground and financials lagging, investors are keenly observing growth opportunities amidst fluctuating conditions. In such an environment, stocks with high insider ownership can be particularly appealing as they often indicate confidence in the company's future prospects.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/3-asx-growth-stocks-with-high-insider-ownership-growing-earn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/3-asx-growth-stocks-with-high-insider-ownership-growing-earn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7142","XAO.AU","BK7016","IR1.AU","BK7095","BK4139","TTT.AU","BK7051","PWH.AU","TLX.AU","EIQ.AU","BK7067","XJO.AU","WZR.AU","BK7104","TLX","3DP.AU","BK7506","BK7036","BK7093","PH2.AU","XKO.AU","LM8.AU","NWF.AU","BK7116","EOL.AU","AV1.AU","EMR.AU"],"gpt_icon":0},{"id":"2585165752","title":"Telix Pharmaceuticals (TLPPF) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2585165752","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585165752?lang=en_us&edition=fundamental","pubTime":"2025-11-21 07:06","pubTimestamp":1763679973,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst David Bailey maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$25.40. According to TipRanks...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-morgan-stanley-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/telix-pharmaceuticals-tlppf-receives-a-buy-from-morgan-stanley-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0267386448.USD","BK4139","LU0106261372.USD","LU1162221912.USD","LU1720051017.SGD","LU1989772923.USD","LU2028103732.USD","LU1244550577.SGD","TLPPF","BK4588","LU0006306889.USD","LU1791710400.SGD","BK4516","LU1732799900.SGD","LU0234570918.USD","BK4581","LU1668664300.SGD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0158827781.USD","LU1244550494.USD","LU0320765646.SGD","LU1720051108.HKD","LU1732800096.USD","LU0912757837.SGD","LU1548497426.USD","LU1363072403.SGD","LU0795875169.SGD","BK4504","LU0795875086.SGD","LU0098860793.USD","LU1791710582.SGD","LU2023251221.USD","LU2357305700.SGD","LU2347655156.SGD","LU0106831901.USD","BK4127","LU2271345857.HKD","TLX","IE00BKVL7J92.USD","LU1074936037.SGD","LU2111349929.HKD","LU0314104364.USD","LU1989772840.SGD","LU0225283273.USD","LU0971096721.USD","LU0158827948.USD","BK4534","BK4585","LU2089283258.USD"],"gpt_icon":0},{"id":"2584788929","title":"ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses","url":"https://stock-news.laohu8.com/highlight/detail?id=2584788929","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584788929?lang=en_us&edition=fundamental","pubTime":"2025-11-20 03:00","pubTimestamp":1763578800,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Nov.  20, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces results from the ZIRCON-X study which finds th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3191353/0/en/ZIRCON-X-Analysis-TLX250-CDx-Impacts-Clinical-Decision-Making-for-Almost-Half-of-Patients-with-Indeterminate-Renal-Masses.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4526","TLX","SOC","BK4213","ASX","BK4543","BK4139","BK4141"],"gpt_icon":0},{"id":"2584609779","title":"ASX Investment Ideas 3 Stocks With Estimated Undervaluation","url":"https://stock-news.laohu8.com/highlight/detail?id=2584609779","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584609779?lang=en_us&edition=fundamental","pubTime":"2025-11-18 03:04","pubTimestamp":1763406284,"startTime":"0","endTime":"0","summary":"As the Australian market grapples with uncertainty, driven by unexpected inflation figures and fluctuating unemployment rates, investors are cautiously navigating a landscape marked by extreme fear on Wall Street. In this environment, identifying undervalued stocks can offer potential opportunities for those looking to capitalize on discrepancies between current stock prices and intrinsic value.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3021000-choice1-main-header/1585186644732"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/asx-investment-ideas-3-stocks-with-estimated-undervaluation","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/capital-goods/asx-dro/droneshield-shares/news/asx-investment-ideas-3-stocks-with-estimated-undervaluation","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CSX.AU","TLX.AU","RPL.AU","BK7070","XAO.AU","BK7115","TLX","CKF.AU","BK7137","GYG.AU","ALQ.AU","BK4139","XJO.AU","SPZ.AU","WJL.AU","DRO.AU","BK7067","BK7062","BK7508","NWH.AU","BK7050","BK7084","SYL.AU","BK7055","BK7047","XKO.AU","BK7007","IMM.AU"],"gpt_icon":0},{"id":"2583541788","title":"Telix Pharmaceuticals Faces Class Action Lawsuit Alleging Misleading Statements Related to Progress of Prostate Cancer Therapy Candidates; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583541788","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583541788?lang=en_us&edition=fundamental","pubTime":"2025-11-14 09:21","pubTimestamp":1763083291,"startTime":"0","endTime":"0","summary":"A class action lawsuit was filed against Telix Pharmaceuticals (ASX:TLX) on behalf of investors in Telix, who acquired securities in the firm between Feb. 21 and Aug. 28, alleging that Telix materiall","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX","PRGS","TLX.AU","BK4097","LU2065732104.USD","BK4139"],"gpt_icon":0},{"id":"2582397371","title":"OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2582397371","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582397371?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:00","pubTimestamp":1762891200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australiaand INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited  today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx  in metastatic triple negative breast cancer  have been published in the European Journal of Nuclear Medicine and Molecular Imaging [2].OPALESCENCE was a prospective, single-center Phase 2 investigator-initiated trial  conducted at the Institut de Cancérologie de l'Ouest  in St Herblain, France. The trial evaluated the safety, sensitivity, and diagnostic utility of TLX250-CDx PET/CT[3] imaging in women with mTNBC.The pilot prospective study of twelve  patients demonstrated the expression of carbonic anhydrase IX  in TNBC and effective tumor targeting with TLX250-CDx:. TLX250-CDx PET/CT detected all brain metastases, confirmed byMRI, whereas FDG PET/CT detected only one-third of brain lesions;No safety issues were reported after TLX250-CDx administration.Telix supplied and authorized ICO to use ","market":"us","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/opalescence-trial-published-in-ejnmmi-confirms-theranostic-potential-of-tlx250-cdx-in-breast-cancer-302611379.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","BK4543","BK7067","TLX","XAO.AU","XJO.AU","BK7039","BK4139","TLX.AU","XKO.AU","BK4526","ASX","ASX.AU","BK4141"],"gpt_icon":0},{"id":"2581041843","title":"Citi Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581041843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581041843?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:36","pubTimestamp":1762468578,"startTime":"0","endTime":"0","summary":"In a report released today, Laura Sutcliffe from Citi maintained a Buy rating on Telix Pharmaceuticals, with a price target of A$34.00. According t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/citi-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0},{"id":"2581265450","title":"Does the SEC Probe Challenge Telix Pharmaceuticals' (ASX:TLX) Management Credibility and Investor Confidence?","url":"https://stock-news.laohu8.com/highlight/detail?id=2581265450","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581265450?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:41","pubTimestamp":1762465275,"startTime":"0","endTime":"0","summary":"Recently, Telix Pharmaceuticals disclosed that it received a subpoena from the U.S. Securities and Exchange Commission concerning its disclosures about prostate cancer therapeutic candidates, prompting law firms such as Bragar Eagel & Squire and Rosen Law Firm to initiate investigations into potential securities law violations.\nThis development has heightened attention to the accuracy of the company’s public statements and their impact on investor trust.\nWe’ll consider how the federal...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-the-sec-probe-challenge-telix-pharmaceuticals-asxtlx-ma","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/does-the-sec-probe-challenge-telix-pharmaceuticals-asxtlx-ma","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2581726794","title":"Telix to Participate in UBS and Jefferies Global Healthcare Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2581726794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581726794?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:00","pubTimestamp":1762340400,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Nov.  05, 2025  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) will participate in the upcoming UBS Global Healthcare Confere","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/05/3181191/0/en/Telix-to-Participate-in-UBS-and-Jefferies-Global-Healthcare-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","LABU","BK4526","LU0029874061.USD","TLX","BK4528","BK4585","ASX","LU0128526141.USD","BK4543","BK4139","BK4205","BK4588","UK","BK4141","XLV","BK4137","XBI","HCSG","BK4233"],"gpt_icon":0},{"id":"2581923714","title":"Telix Pharmaceuticals (ASX:TLX): Examining Valuation After SEC Subpoena and Ongoing Legal Probes","url":"https://stock-news.laohu8.com/highlight/detail?id=2581923714","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581923714?lang=en_us&edition=fundamental","pubTime":"2025-11-05 06:37","pubTimestamp":1762295843,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has disclosed that it received a subpoena from the U.S. Securities and Exchange Commission regarding statements about its prostate cancer therapeutics. This has prompted several law firms to investigate possible securities violations.\nSee our latest analysis for Telix Pharmaceuticals.\nThe pressure from regulatory scrutiny and legal investigations has weighed on Telix Pharmaceuticals’ momentum, with the share price dropping 33.9% year-to-date and the 1-year...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-examining-valuation-after-sec-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-examining-valuation-after-sec-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TLX.AU","TLX","DCF","BK7067"],"gpt_icon":0},{"id":"2579111393","title":"Is the SEC Subpoena Shifting the Risk Landscape for Telix Pharmaceuticals (ASX:TLX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2579111393","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579111393?lang=en_us&edition=fundamental","pubTime":"2025-10-30 14:37","pubTimestamp":1761806253,"startTime":"0","endTime":"0","summary":"In recent days, Telix Pharmaceuticals disclosed it received a subpoena from the U.S. Securities and Exchange Commission concerning its disclosures about prostate cancer therapeutic candidates, prompting the Rosen Law Firm to announce an investigation into potential securities violations on behalf of shareholders.\nThis regulatory development highlights the increased scrutiny around pharmaceutical company disclosures and raises questions about transparency in clinical program...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/is-the-sec-subpoena-shifting-the-risk-landscape-for-telix-ph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/is-the-sec-subpoena-shifting-the-risk-landscape-for-telix-ph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX","TLX.AU"],"gpt_icon":0},{"id":"2579915890","title":"Telix Pharmaceuticals to Release Shares from Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2579915890","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579915890?lang=en_us&edition=fundamental","pubTime":"2025-10-29 06:18","pubTimestamp":1761689888,"startTime":"0","endTime":"0","summary":"An announcement from Telix Pharmaceuticals ( ($AU:TLX) ) is now available. Telix Pharmaceuticals announced the release of 45,584 ordinary shares fr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-9?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-9?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","BK4139"],"gpt_icon":0},{"id":"2578638679","title":"How Does Regulatory Scrutiny Impact Telix Pharmaceuticals (ASX:TLX) Valuation?","url":"https://stock-news.laohu8.com/highlight/detail?id=2578638679","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578638679?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:14","pubTimestamp":1761592490,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) recently revealed it received a subpoena from the U.S. Securities and Exchange Commission regarding its prostate cancer drug disclosures. This has sparked legal investigations into whether shareholders may have been misled.\nSee our latest analysis for Telix Pharmaceuticals.\nEven with regulatory scrutiny weighing on sentiment, Telix Pharmaceuticals has managed several positive milestones in recent months, including upgraded earnings guidance and the launch of a...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-does-regulatory-scrutiny-impact-telix-pharmaceuticals-as","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/how-does-regulatory-scrutiny-impact-telix-pharmaceuticals-as","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","BK4139","TLX.AU","TLX","DCF"],"gpt_icon":0},{"id":"2578069631","title":"Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (ASX:TLX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2578069631","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578069631?lang=en_us&edition=fundamental","pubTime":"2025-10-26 18:19","pubTimestamp":1761473956,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$23.00. The company’s shares clos...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-asxtlx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-asxtlx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX"],"gpt_icon":0},{"id":"2577537753","title":"Telix Pharmaceuticals to Release Shares from Voluntary Escrow","url":"https://stock-news.laohu8.com/highlight/detail?id=2577537753","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577537753?lang=en_us&edition=fundamental","pubTime":"2025-10-24 06:17","pubTimestamp":1761257876,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an update. Telix Pharmaceuticals announced the release of 1,649,037 ordinary shares from voluntary e...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-8?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-pharmaceuticals-to-release-shares-from-voluntary-escrow-8?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"gpt_icon":0},{"id":"2577055373","title":"TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging","url":"https://stock-news.laohu8.com/highlight/detail?id=2577055373","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577055373?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:00","pubTimestamp":1761217200,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ --Telix Pharmaceuticals Limited  today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging , the European Association of Nuclear Medicine  and The American College of Nuclear Medicine  that, for the first time, include the use of Telix's investigational PET[1] agent, TLX250-CDx , for molecular imaging of renal masses.Published on the SNMMI website[3] and in The Journal of Nuclear Medicine[4], the guideline panel[5], comprising internationally renowned and multidisciplinary expert key opinion leaders, concludes that \"the emerging use of molecular imaging for risk stratification of indeterminate renal masses offers the opportunity to more effectively characterize such lesions and optimize patient management decisions\".Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, added, \"The inclusion of TLX250-CDx PET imaging for the first time in SNMMI/EANM/ACNM guidelines is an ","market":"hk","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/tlx250-cdx-zircaix-included-in-leading-international-guidelines-for-renal-imaging-302592411.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7039","TLX.AU","BK4141","BK7067","XAO.AU","TLX","XJO.AU","BK4543","BK4526","XKO.AU","SEC.AU","ASX.AU","ASX","BK4139"],"gpt_icon":0},{"id":"2577439503","title":"Bell Potter Sticks to Their Buy Rating for Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2577439503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577439503?lang=en_us&edition=fundamental","pubTime":"2025-10-23 07:05","pubTimestamp":1761174330,"startTime":"0","endTime":"0","summary":"Bell Potter analyst John Hester maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$23.00. The company’s shares clos...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bell-potter-sticks-to-their-buy-rating-for-telix-pharmaceuticals-tlppf-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLX","TLPPF"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":70,"code":"91000000","status":"200"}]}}